| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
2e-11 |
| mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
5e-11 |
| mRNA |
GSK461364 |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
2e-10 |
| mRNA |
3-Cl-AHPC |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
6e-10 |
| mRNA |
Genentech Cpd 10 |
GDSC1000 |
pan-cancer |
AAC |
0.2 |
7e-10 |
| mRNA |
navitoclax:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
9e-10 |
| mRNA |
THZ-2-102-1 |
GDSC1000 |
pan-cancer |
AAC |
0.19 |
3e-09 |
| mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
3e-09 |
| mRNA |
Topotecan |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
5e-09 |
| mRNA |
FQI-2 |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
5e-09 |